HEALTH OF WOMAN.2015.1(97):150–153; doi 10.15574/HW.2015.97.150 
 

Serum levels of endothelial monocyte-activating polypeptide-II in patients with polycystic ovary syndrome with different body mass 
 

Mogylnytska L. A.

Khmelnytskyi regional hospital 
 

The study found increasing of serum levels of endothelial monocyte-activating polypeptide-II (EMAP-II) in patients with polycystic ovary syndrome (PCOS) obese and normal weight compared with the control group. In the group of patients with PCOS as obese and normal weight found correlation between the serum levels of EMAP-II and BMI, HOMA index, lipid metabolism, androgens. Revealed changes may indicate the development of endothelial dysfunction in patients with PCOS. 
 

Key words: endothelial monocyte-activating polypeptide-II, polycystic ovary syndrome, insulin resistance, endothelial dysfunction. 
 

REFERENCES

1. Battersby S., Boddy S.C., Critchley H.O., Jabbour H.N. 2002. Expression and localization of endothelial monocyte-activating polypeptide II in the human endometrium across the menstrual cycle: regulation of expression by prostaglandin E(2). J Clin. Endocrinol. Metab. 87:3928–3935. http://dx.doi.org/10.1210/jcem.87.8.8719; PMid:12161535

2. Corbould A. 2007. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J. Endocrinol. 192:585–594. http://dx.doi.org/10.1677/joe.1.07070; PMid:17332526

3. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. 2005. The molecular genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr. Rev. 26:251–282. http://dx.doi.org/10.1210/er.2004-0004; PMid:15561799

4. Ferriman D., Gallwey J.D. 1962. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 21:1440–1447. http://dx.doi.org/10.1210/jcem-21-11-1440; PMid:13892577

5. Gonzбlez F. 2012. Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 77 (4):300–5. http://dx.doi.org/10.1016/j.steroids.2011.12.003; PMid:22178787 PMCid:PMC3309040

6. Juonala M., Magnussen C.G., Berenson G.S., et al. 2011. Childhood adiposity, adult adiposity, and cardiovascular risk factors. New Engl. J. Med. 365:1876–1885. http://dx.doi.org/10.1056/NEJMoa1010112; PMid:22087679

7. Kao J., Houck K., Fan Y., Haehnel I., Libutti S.K., Kayton M.L., et al. 1994. Characterization of a novel tumor-derived cytokine. Endothelialmonocyte activating polypeptide II. J. Biol. Chem. 269:25106–25119. PMid:7929199

8. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM. 2002. Altered vascular function in young women with polycystic ovary syndrome. J Clin. Endocrinol. Metab. 87:742–746. http://dx.doi.org/10.1210/jcem.87.2.8199; PMid:11836314

9. Legro R.S., Finegood D., Dunaif A. 1998. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83:2694–2698. http://dx.doi.org/10.1210/jcem.83.8.5054; http://dx.doi.org/10.1210/jc.83.8.2694; PMid:9709933

10. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Trecher D.F., Turner D.C. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412–419. http://dx.doi.org/10.1007/BF00280883; PMid:3899825

11. Muolokwu E., Sanchez J., Bercaw J.L., et al. 2011. Paratubal cysts, obesity, and hyperandrogenism. J. Pediatr. Surg. 46:2164–2167. http://dx.doi.org/10.1016/j.jpedsurg.2011.07.011; PMid:22075351

12. Norman R.J., Dewailly D., Legro R.S., Hickey T.E. 2007. Polycystic ovary syndrome. Lancet. 370:685–697. http://dx.doi.org/10.1016/S0140-6736(07)61345-2

13. Orio F.Jr, Palomba S., Spinelli L. et al. 2004. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case–control study. J Clin. Endocrinol. Metab. 89:3696–3701. http://dx.doi.org/10.1210/jc.2003-032049; PMid:15292291

14. Pasquali R., Gambineri A., Pagotto U. 2006. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 113:1148–1159. http://dx.doi.org/10.1111/j.1471-0528.2006.00990.x; PMid:16827825

15. Rexrode K.M., Manson J.E., Lee I.M., et al. 2003. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 108:1688–1693. http://dx.doi.org/10.1161/01.CIR.0000091114.36254.F3; PMid:12975257

16. Rossi B., Sukalich S., Droz J., et al. 2008. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93:4780–4786. http://dx.doi.org/10.1210/jc.2008-1198; PMid:18812482 PMCid:PMC2626442

17. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum. Reprod. 2004. 19:41–47. PMid:14688154

18. Toscani M.K., Mario F.M., Radavelli-Bagatini S., Spritzer P.M. 2011. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome. Nutr. Res. 31:97–103. http://dx.doi.org/10.1016/j.nutres.2011.01.009; PMid:21419313

19. Tzeng C.R., Chang Y.C., Chang Y.C. 2014. Cluster analysis of cardiovascular and metabolic risk factors in women of reproductive age. Fertil. Steril. 101 (5):1404–10. http://dx.doi.org/10.1016/j.fertnstert.2014.01.023; PMid:24534286

20. Vermeulen A., Verdonck L., Kaufman J.M. 1999. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84:3666–3672. http://dx.doi.org/10.1210/jcem.84.10.6079; PMid:10523012

21. Wellings R.P., Lash G.E., Murray J.C., et al. 1999. Endothelial monocyte-activating polypeptide-2 is increased in pregnancy but is not further increased in preeclampsia. J. Soc. Gynecol. Invest. 6:142–146. http://dx.doi.org/10.1016/S1071-5576(99)00011-8

22. Wojciechowski P., Lipowska A., Rys P., et al. 2012. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia 55:2636–2645. http://dx.doi.org/10.1007/s00125-012-2638-6; http://dx.doi.org/10.1007/s00125-012-2664-4; PMid:22801903

23. Xu N., Kwon S., Abbott D.H., et al. 2011. Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys. PLoS ONE 6:272–286. http://dx.doi.org/10.1371/journal.pone.0027286; PMid:22076147 PMCid:PMC3208630

24. Yildiz B.O., Azziz R. 2010. Ovarian and adipose tissue dysfunction in polycystic ovary syndrome:report of the 4th special scientific meeting of the Androgen Excess and PCOS Society. Fertil. Steril. 94:690–693. http://dx.doi.org/10.1016/j.fertnstert.2009.03.058; PMid:19394000 PMCid:PMC3727143